Andrew is a seasoned professional with a diverse background in scientific innovation and business leadership. Prior to joining Inoviv as the Director of Discovery & Technology, Andrew served as Head of Chemical Proteomics at Proteome Sciences, where he led groundbreaking initiatives in the development of the “TMT-pro-16-plex”, a significant advancement in mass spectrometry-based proteomics. His efforts in optimizing workflows and expanding the product pipeline contributed to strengthening the company’s position in the market. Additionally, Andrew also served as the Chief Scientific Officer at Trillion Genomics, where he led the creation of a diverse product portfolio. He spearheaded the development of novel technologies, including MALDI Imaging tags, LNA Discontinuous Probes, and asymmetric PCR methods, aimed at high-specificity diagnostics and antisense targeting applications.